• Blog
  • Hereditary Angioedema Market Analysis | 2021-2026

    Hereditary Angioedema Market Analysis | 2021-2026

    Hereditary Angioedema Market Analysis | 2021-2026
    Report code - SR1529 Delivery - 2 Weeks
    Hereditary Angioedema Market Growth, Trends, Dynamics & Market Insights: 2021-2026
    See more...

    Market Insights

    The Hereditary Angioedema Market is projected to grow from USD 1.9 billion in 2020 to USD 2.8 billion by 2026 at a CAGR of around 7.2% during the forecast period.

    Wish to get a free sample? Register Here

    What is hereditary angioedema?

    Hereditary angioedema is a genetic disorder characterized by persistent episodes of severe swelling (angioedema). It most commonly affects limbs, intestinal tract, face, and airway. It can be classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). 

    Hereditary Angioedema Market Report Overview

    Market Size in 2026

    USD 2.8 billion

    Market Size in 2020

    USD 1.9 billion

    Market Growth (2021-2026)

    CAGR of 7.2%

    Base Year of Study

    2020

    Trend Period

    2016-2019

    Forecast Period

    2021-2026

    Key Players

    Key players operating in the Hereditary Angioedema market are-

    • Pharming Group NV (Netherlands)
    • Shire plc (US)
    • CSL Limited (Australia)
    • iBio Inc. (US)
    • BioCryst Pharmaceuticals, Inc. (US)
    • Ionis Pharmaceuticals (US)
    • Sanofi S.A. (France)
    • Attune Pharmaceuticals, Inc. (US)
    • Adverum Biotechnologies, Inc. (US).

    Market Dynamics

    The growth of the hereditary angioedema market is primarily driven by rising incidences of hereditary angioedema across geographies. Growing emphasis on initiatives aimed at creating awareness among consumers related to the disease is expected to augment the market growth substantially. In addition to this, increasing investment in research and development activities to develop a novel drug is likely to create lucrative opportunities for the players operating in the global hereditary angioedema market in the coming years.

    COVID-19 Impact

    The covid-19 outbreak posed significant challenges across verticals worldwide. It impacted the growth of the hereditary angioedema market negatively as the diagnostic procedures other than covid-19 treatment declined due to fear of coronavirus infection. Also, supply chain disruptions due to the imposition of the lockdown affected the product availability on time and thus, affected the market growth.

    To get the full scope of the report, Register Here

    Segment Analysis

    End-Use Trends

    The hereditary angioedema market has been bifurcated into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment accounted for the largest market share in 2020 and is projected to register significant growth during the review period. The segment can be attributed to the convenience and availability of drugs.

    Regional Analysis

    The North American market accounted for the largest market share in 2020 and is projected to grow at a robust CAGR during the review period. This can be attributed to the expanding geriatric populace and increasing investment in R&D activities to develop new drugs coupled with the presence of key market players such as Shire plc (US) and BioCryst Pharmaceuticals, Inc. (US). The market growth in Asia-Pacific is expected to be driven by an increasing number of people having hereditary angioedema disease.

    To know which region offers the best growth opportunities, Register Here

    Target Audience

    Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

    What deliverables will you get in this report?

    Key questions this report answers

    Relevant contents in the report

    How big is the sales opportunity?

    In-depth analysis of the Hereditary Angioedema Market

    How lucrative is the future?

    Market forecast and trend data and emerging trends

    Which regions offer the best sales opportunities?

    Global, regional and country level historical data and forecasts

    Which are the most attractive market segments?

    Market segment analysis and forecast

    Which are the top players and their market positioning?

    Competitive landscape analysis, Market share analysis

    How complex is the business environment?

    Porter’s five forces analysis, PEST analysis, Life cycle analysis

    What are the factors affecting the market?

    Drivers & challenges

    Will I get the information on my specific requirement?

    10% free customization

    Research Methodology

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Customization Options

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The hereditary angioedema market is expected to witness an impressive growth of 7.2% CAGR in the coming years.

    Pharming Group NV (Netherlands), Shire plc (US), CSL Limited (Australia), iBio Inc. (US), Bio-Cryst Pharmaceuticals, Inc. (US), Ionis Pharmaceuticals (US), Sanofi S.A. (France), Attune Phar-maceuticals, Inc. (US) and Adverum Biotechnologies, Inc. (US) are among the key players in the hereditary angioedema market.

    The hereditary angioedema market size is expected to reach USD 2.8 billion in the foreseeable future.

    The hospital pharmacies segment is expected to register significant growth in the hereditary angioedema market in the coming years.

    North America accounted for the largest share in the hereditary angioedema market in 2020.

    The growth of the hereditary angioedema market is primarily driven by rising incidences of hereditary angioedema across geographies. Growing emphasis on initiatives aimed at creating awareness among consumers related to the disease is expected to augment the market growth substantially. In addition to this, increasing investment in research and development activities to develop a novel drug is likely to create lucrative opportunities for the players operating in the global hereditary angioedema market in the coming years.